Pulmatrix, a clinical stage bio-pharmaceutical firm advancing innovative therapies via inhalation to address serious pulmonary diseases, has recently announced it has entered into a partnership with Mylan N.V., which is a leading worldwide global pharmaceutical company. The agreement includes the ongoing development of PUR0200, a clinical stage bronchodilator therapy currently being assessed to address chronic obstructive pulmonary disease (COPD), and iSPERSE™, an inhaled dry powder technology. PUR0200 is being advanced in a capsule-based dry powder inhaler (DPI) and as a once-daily therapy.
PUR0200 features a long-acting muscarinic agent (LAMA) being evaluated to treat COPD, and current clinical development is focused on studying its pharmacokinetic bioequivalence in Europe. The IMS Health believes that global sales of LAMA monotherapies to address COPD represented $5 billion in 2014 and $1.5 billion in sales outside the United States.
Pulmatrix’s CEO Robert Clarke said: “Our agreement with Mylan for the development of PUR0200 is a major step for Pulmatrix and the continued development of our iSPERSE technology. At the current stage of development of PUR0200 and goals of the program, Mylan is the ideal partner to bring this product forward for COPD patients.”
Rajiv Malik, from Mylan, noted: “Mylan is excited to partner with Pulmatrix on this potential generic LAMA DPI opportunity. This collaboration demonstrates our continued commitment to building our global respiratory pipeline, a key strategic growth driver for the company.”
Pulmatrix will be leading the advancement of the pharmacokinetic clinical study and, in keeping with the terms of their new agreement, will collaborate with Mylan in overall development efforts.
The company seeks to improve patient outcomes through its product candidates that are mainly based on iSPERSE, a drug delivery platform that maximizes therapeutic delivery to the lungs while reducing systemic side effects.
Mylan is a global pharmaceutical firm focused on establishing new standards in healthcare. The company works to provide access to top quality medicines that may address unmet needs. The company is developing a growing portfolio and operates in 145 countries and includes over 30,000 employees.
Read More Recent News
Breathe Technologies, Inc. recently announced that the United States Food and Drug Administration (FDA) has approved its critical care Breathe Technologies Life2000 Ventilation System. The device is designed to provide both continuous and intermittent ventilatory support to care for patients who need mechanical ventilation.